Oncolytics Biotech (ONCY) names new COO and grants 96,000-share option to director
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Oncolytics Biotech Inc. announced leadership changes, appointing John McAdory as Chief Operating Officer and adding Steve Glover to its Board of Directors. McAdory, age 49, previously led clinical operations roles at CG Oncology, SillaJen, UCB, and Amgen, and will oversee clinical, preclinical, and development activities as well as strategic partnerships.
Glover, age 66, becomes the ninth director and received an option to purchase 96,000 common shares, vesting in three equal annual installments of 32,000 shares starting one year after June 1, 2026. He brings more than 35 years of biopharma leadership, including chairing Ambrx Biopharma through its approximately $2 billion acquisition by Johnson & Johnson and co-founding Coherus BioSciences. The company emphasizes these appointments as supporting advancement of pelareorep, its investigational immunotherapy platform.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 5.02, 8.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
McAdory age: 49 years
Glover age: 66 years
Director option grant: 96,000 shares
+4 more
7 metrics
McAdory age
49 years
Age of newly appointed COO John McAdory
Glover age
66 years
Age of newly appointed director Steve Glover
Director option grant
96,000 shares
Stock options granted to Steve Glover on June 1, 2026
Annual vesting tranche
32,000 shares
Number of option shares vesting each year over three years
Ambrx deal value
approximately $2 billion
Transaction value for Ambrx Biopharma acquisition by Johnson & Johnson
Board size
nine directors
Steve Glover appointed as the ninth director
Phase 3 reference
pivotal Phase 3 program
McAdory’s prior CG Oncology experience
Key Terms
pivotal Phase 3 program, Fast Track designation, registration-enabling studies, checkpoint inhibitors, +2 more
6 terms
pivotal Phase 3 program medical
"he led clinical operations through its pivotal Phase 3 program and initial public offering"
Fast Track designation regulatory
"pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
registration-enabling studies medical
"as we advance our registration-enabling studies, expand our preclinical pipeline"
checkpoint inhibitors medical
"advancing pelareorep in combination with chemotherapy and/or checkpoint inhibitors in metastatic gastrointestinal cancers"
Checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking certain proteins that normally keep immune responses in check. They act like brakes being released on the immune system, allowing it to target tumors more effectively. These medicines are important for investors because they represent a promising area of cancer treatment with growing research, development, and commercial potential.
indemnification agreement regulatory
"has entered into an indemnification agreement with the Company providing for the indemnification of, and advancement of expenses to"
An indemnification agreement is a contract in which one party promises to cover losses, costs, or legal claims that another party might face, acting like a tailored safety net or private insurance policy. For investors, it matters because such agreements shift potential financial risk away from a company or its officers and onto the indemnifier, which can affect a company’s future liabilities, cash flow and how risky the investment appears during deal-making or litigation.
independent director regulatory
"Mr. Glover qualifies as an independent director under the independence requirements set forth under Rule 5605(a)(2)"
An independent director is a member of a company's board of directors who is not involved in the company's day-to-day operations and has no significant relationships with the company that could influence their judgment. Their role is to provide unbiased oversight and ensure the company is managed in the best interests of all shareholders. This helps build trust and confidence among investors by promoting transparency and accountability.
FAQ
What leadership changes did Oncolytics Biotech (ONCY) announce in this 8-K?
Oncolytics Biotech appointed John McAdory as Chief Operating Officer and Steve Glover as its ninth director. McAdory will oversee clinical and development activities, while Glover adds extensive public company and transaction experience to the Board.
What equity compensation did Steve Glover receive from Oncolytics Biotech (ONCY)?
Steve Glover received a stock option to purchase 96,000 shares of common stock at the June 1, 2026 Nasdaq closing price. The option vests in three equal annual installments of 32,000 shares, contingent on his continued Board service.
What is John McAdory’s background before becoming COO of Oncolytics Biotech (ONCY)?
Before becoming COO, John McAdory served as Executive Vice President, Strategy and Operations at Oncolytics and previously was Vice President, Clinical Operations at CG Oncology, Head of Clinical Operations at SillaJen, and held clinical roles at UCB and Amgen.
Why did Oncolytics Biotech (ONCY) add Steve Glover to its Board of Directors?
The Board cited Steve Glover’s extensive executive and public company board experience in pharmaceuticals and biotech. His leadership at Ambrx Biopharma during its approximately $2 billion sale to Johnson & Johnson was highlighted as particularly relevant experience.
What is pelareorep, the therapy Oncolytics Biotech (ONCY) is developing?
Pelareorep is an investigational intravenously delivered double-stranded RNA immunotherapeutic agent. It aims to convert immunologically “cold” tumors to “hot,” enhancing anti-cancer immune responses and has shown encouraging data in pancreatic, metastatic breast, anal, and colorectal cancers.
In which indications has pelareorep received FDA Fast Track designation?
Pelareorep has received Fast Track designation from the FDA for use in colorectal cancer and pancreatic cancer. Oncolytics is advancing the therapy mainly in metastatic gastrointestinal cancers, often in combination with chemotherapy and checkpoint inhibitors.